These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17566521)

  • 1. [Antipsychotic-induced symptomatic hyperprolactinemia: clinical consequences and therapeutic strategies].
    Pollice R; Di Giovambattista E; Tomassini A; Di Pucchio A; Ussorio D; Roncone R; Casacchia M
    Clin Ter; 2007; 158(2):173-9. PubMed ID: 17566521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
    Compton MT; Miller AH
    Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M; Suppes T; Tran QV; Baker RA
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-induced hyperprolactinemia.
    Bostwick JR; Guthrie SK; Ellingrod VL
    Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L; Eap CB
    J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL
    Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
    Hummer M; Huber J
    Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of psychotropic-induced hyperprolactinemia.
    Marken PA; Haykal RF; Fisher JN
    Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.
    Maguire GA
    J Clin Psychiatry; 2002; 63 Suppl 4():56-62. PubMed ID: 11913677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients].
    Konarzewska B; Szulc A; Popławska R; Galińska B; Juchnowicz D
    Psychiatr Pol; 2008; 42(1):87-95. PubMed ID: 18567406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal side effects in women: typical versus atypical antipsychotic treatment.
    Dickson RA; Seeman MV; Corenblum B
    J Clin Psychiatry; 2000; 61 Suppl 3():10-5. PubMed ID: 10724128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice.
    Smith S
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S27-32. PubMed ID: 12832947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia.
    Poyraz BC; Aksoy C; Balcioğlu I
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):667-72. PubMed ID: 18539008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
    Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
    J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
    Johnsen E; Kroken RA; Abaza M; Olberg H; Jørgensen HA
    J Clin Psychopharmacol; 2008 Dec; 28(6):686-90. PubMed ID: 19011438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
    Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
    Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.